Aktis Oncology (NASDAQ:AKTS – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $35.62.
Several equities analysts have commented on AKTS shares. BMO Capital Markets began coverage on shares of Aktis Oncology in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $35.00 price objective on shares of Aktis Oncology in a research note on Friday, October 2nd. Raymond James Financial reiterated a “strong-buy” rating on shares of Aktis Oncology in a report on Tuesday. Wall Street Zen cut Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Finally, Oppenheimer started coverage on Aktis Oncology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $40.00 target price for the company.
View Our Latest Analysis on Aktis Oncology
Hedge Funds Weigh In On Aktis Oncology
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Aktis Oncology by 7.9% during the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock worth $73,431,000 after buying an additional 166,231 shares during the period. Blue Owl Capital Holdings LP lifted its stake in Aktis Oncology by 8.9% in the third quarter. Blue Owl Capital Holdings LP now owns 3,343,827 shares of the technology company’s stock worth $65,104,000 after acquiring an additional 273,608 shares during the last quarter. Wellington Management Group LLP purchased a new position in Aktis Oncology in the second quarter worth approximately $63,372,000. Jupiter Topco LLC purchased a new position in Aktis Oncology in the second quarter worth approximately $42,359,000. Finally, State Street Corp grew its holdings in Aktis Oncology by 8.5% during the 3rd quarter. State Street Corp now owns 1,050,480 shares of the technology company’s stock worth $20,453,000 after acquiring an additional 82,460 shares in the last quarter. Hedge funds and other institutional investors own 28.84% of the company’s stock.
Aktis Oncology Stock Performance
NASDAQ AKTS opened at $16.40 on Friday. The firm has a market cap of $884.29 million and a price-to-earnings ratio of -12.06. The firm has a 50 day simple moving average of $17.84 and a 200-day simple moving average of $20.70. Aktis Oncology has a one year low of $13.96 and a one year high of $34.19.
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last announced its earnings results on Thursday, November 12th. The technology company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.07). The business had revenue of $3.91 million for the quarter, compared to analysts’ expectations of $4.87 million. Aktis Oncology had a negative return on equity of 26.86% and a negative net margin of 706.81%. Equities analysts predict that Aktis Oncology will post -1.97 EPS for the current fiscal year.
Aktis Oncology Company Profile
Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.
Featured Stories
- Five stocks we like better than Aktis Oncology
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
